Investor Presentation Full Year 2021
112
Investor presentation Full year 2021
Innovation drives largest transition in the history of Novo
Nordisk USA, turning around 70% of sales in just seven years
Directional growth drivers and catalysts
100%
GLP-1
Obesity
Insulin
Biopharm
80%
•
OzempicⓇ launch
RybelsusⓇ launch
Victoza® LoE
•
WegovyⓇ launch
•
SaxendaⓇ LOE
Continued price
pressure
Competitive
60%
pressure
• Biosimilar
competition
New product
launches
40%
20%
1 Modern insulin, human insulin, PrandinⓇ, devices and needles; 2 OzempicⓇ and Rybelsus®, 3 TresibaⓇ, Xultophy, FiaspⓇ and follow-on brand insulin
LoE: Loss of exclusivity
0%
NAO
Relative sales composition -
60% transformation complete
ILLUSTRATIVE
2015
Biopharm
Mature insulin¹
2022
Victoza®
Obesity
New GLP-1
launches²
New insulin
launches³
30%View entire presentation